Santen to award performance-linked shares, updates share buyback program

Santen Pharmaceutical will dispose of 57,909 shares of its common stock on October 31, 2025, as part of its post-delivery performance-linked stock remuneration plan. The total value of these shares is 94,941,804 yen, calculated at 1,639.5 yen per share, based on the closing price on September 30, 2025. These shares will be allotted to 2 directors (excluding outside directors), 4 corporate officers, and 2 former employees. The compensation is based on performance from fiscal year 2022 to fiscal year 2024, with a payout ratio of 142.6% for achieving specific Relative TSR and Dow Jones Sustainability Index scores.

In a related announcement, Santen also detailed the status of its ongoing share buyback program. From September 1 to September 30, 2025, the company repurchased 2,772,000 common shares for a total of 4,508,303,950 yen. This brings the cumulative shares repurchased under the current resolution to 16,575,400 shares, totaling 26,897,349,250 yen, against a maximum authorized buyback of 19,800,000 shares and 35 billion yen.